


Biotech & Materials engineering Using IP for Leapfrog Strategy



Creating & implementing breakthrough technologies



Prof Archana Bhaw-Luximon

Biomaterials Engineering and Nanomedicine CBBR, University of Mauritius Mauritius <u>a.luximon@uom.ac.mu</u> 26 April 2023

Copyright, Bhaw-Luximon A et al



Institutional Autonomy Academic Freedom Integrity


Respect Responsibility Equity

Passionate & Innovate Beyond Boundaries

We live our values

www.uom.ac.mu

ChatGPT – thought process



- Step 1 Intellectual property creations of the mind
- Step 2 Intellectual property rights patents, trademarks, copyrights, trade secrets, industrial designs. These rights give creators control over how their creations are used and marketed.
- Intellectual property is essential for innovation and economic growth, as it encourages investment in research and development.
 Ensure that individuals/companies are rewarded for their creative efforts, thus incentivizing further innovation.



Our World: Materials Age Challenges

- Equitable healthcare
- Reliable energy
- Clean water
- Food security
- Mitigating climate change



Need: **Powerful** tools for radical changes.

Need: to create ecosystem

Biotech Companies

ChatGPT

11:41

- Company that specializes in developing and producing products based on biological processes or using living organisms, such as bacteria or genetically modified cells.
- Focus on developing new drugs, vaccines, and medical devices to improve human health, agriculture and environmental solutions.
- These companies often require significant investments due to the high cost of research and development and regulatory compliance.

Current situation

- Fintech startups have better chances of raising funds because they bring revenue faster.
- Investors are not willing to give entrepreneurs time to grow their business.
- Nordic, US, Europe investors understand that it takes time to grow a successful business.
- Entrepreneurship requires a positive mindset and consistency to reach your goal. Entrepreneurs have to be ready, because you will face challenges along your journey.
- Entrepreneur receives a lot of rejections & challenges, mentally strong and believe in yourself and your idea.



Center for Biomedical and Biomaterials Research (CBBR)

'Spin-off' center of UoM Faculty, established 2011





Research & Innovation Thrusts

Design and Engineering of Smart Materials

Collaboration Industry

High-end Analytical services Problem solving Biotech & Materials Engineering projects

Discover, Innovate, Solve





Institutional Autonomy Academic Freedom Integrity

We live our values


Responsibility Equity

Respect


www.uom.ac.mu




CBBR 11-YEAR HISTORY




Leapfrog Future – breakthrough technologies Technical Excellence to Startup to Scale-up Nation How to start the machinery -




Diversify our Core Science & Engineering **Business**




Program Status



Scarless tissue regeneration after a wound




Cranial defect



Cell encapsulation for subcutaneous implants for insulin production


Beta-TC-6 cell line spheroids isolated from the pancreas of a mouse encapsulated into scaffolds




SiR Hoescht DNA_610-6 JASP Actin

(CBBR & Max Planck Institute for Medical Research, Germany)

Cancer regenerative medicine









CBBR, University of Mauritius & Wits Advanced Drug Delivery Platform, University of Witwatersrand, South Africa




Tumour reduction approx. 7% of treatment compared to the control with 11% increase in tumour volume after 96 hours.


Cancer cells


Fibroblasts + cancer cells

AI/machine learning to accelerate process development since 2020



R. Soc. Open Sci. 7: 201293.https://doi.org/10.1098/rsos.201293, December 2020





Predict Inflammation responses through image processing



Creating & implementing breakthrough technologies

Current Researchers

Biomaterials, Drug Delivery and Nanotechnology (BDDN) Unit (approx. 80% Industry funded)

Prof Archana Bhaw-Luximon Dr Nowsheen Goonoo Dr Itisha Chummun Phul Mr Devesh Bekah Dr Yash Boyjoo Ms Tejaswini Petkar Dr Abha Jodheea-Jutton **MPhil/PhD** Mr Avin Ramanjooloo, Mr Akash Nundloll Ms Lakshmi Sujeeun, Ms Laetitia Hüet **CYROI, La Réunion, Pre-Clinical Trials Team** Dr Fanny Gimié (Veterinary and President Ethics Committee, La Réunion) Dr Colette Cordonin (Biochemist), Mr Imade Ait Arsa (Biochemist engineer) **University of Witwatersand, South Africa – Pre-clinical/Pharmacy team**: Prof Yahya Choonara, South African NRF Research Chair and Director, Wits Advanced Drug Delivery Platform (WADDP)

Industry Partners

Mr Kendall Tang, CEO RT Knits Ltd Mr Yannis Fayd'Herbe, MD, Ingenia Ltd Mr Thierry de Speville, Avipro/Eclosia Group

Biotech Strategy Mentors: Mrs Isabelle de Melo, Mo Angels, Kendall Tang, RT Knits Prof Robert Langer & Prof Ram Sasisekharan, MIT